Kate Bingham, MBA, is a manager partner of SV Health Investors. She currently serves or has served on the boards of companies in the U.K., U.S., Ireland, Sweden and Germany. She has been responsible for biotech investments and activities in the EU, including past investments in Alantos, Auxilium, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, Mednova, Micromet, PowderMed and RespiVert.
Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Boston and at Monitor Company, a strategy consulting firm. She has a first-class degree in biochemistry from Oxford University and graduated from Harvard Business School with an MBA.